IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9782408 B1

PDFFull Text
Date of Patent:
Oct. 10, 2017

Filed:

Oct. 06, 2015

Modulators of cystic fibrosis transmembrane conductance regulator

Applicant:

Vertex Pharmaceuticals Incorporated, Boston, MA (US);

Inventors:

Mark Thomas Miller, San Diego, CA (US);

Corey Anderson, San Diego, CA (US);

Vijayalaksmi Arumugam, San Marcos, CA (US);

Brian Richard Bear, Carlsbad, CA (US);

Hayley Marie Binch, Encinitas, CA (US);

Jeremy J. Clemens, San Diego, CA (US);

Thomas Cleveland, San Diego, CA (US);

Erica Conroy, Columbus, OH (US);

Timothy Richard Coon, Carlsbad, CA (US);

Bryan A. Frieman, La Jolla, CA (US);

Peter Diederik Jan Grootenhuis, San Diego, CA (US);

Raymond Stanley Gross, Poway, CA (US);

Sara Sabina Hadida Ruah, La Jolla, CA (US);

Haripada Khatuya, San Diego, CA (US);

Pramod Virupax Joshi, San Diego, CA (US);

Paul John Krenitsky, San Diego, CA (US);

Chun-Chieh Lin, San Diego, CA (US);

Gulin Erdogan Marelius, San Diego, CA (US);

Vito Melillo, Escondido, CA (US);

Jason McCartney, Cardiff by the Sea, CA (US);

Georgia McGaughey Nicholls, Winchester, MA (US);

Fabrice Jean Denis Pierre, La Jolla, CA (US);

Alina Silina, San Diego, CA (US);

Andreas P. Termin, Encinitas, CA (US);

Johnny Uy, San Diego, CA (US);

Jinglan Zhou, San Diego, CA (US);

Assignee:

Vertex Pharmaceuticals Incorporated, Boston, MA (US);

Attorney:

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Primary Examiner:

Heidi Reese

Int. Cl.
CPC ...
A61K 31/506 (2006.01); C07D 213/82 (2006.01); A61K 31/4418 (2006.01); A61K 31/444 (2006.01); A61K 31/44 (2006.01); C07D 213/84 (2006.01); C07D 231/14 (2006.01); A61K 31/415 (2006.01); C07D 209/42 (2006.01); A61K 31/404 (2006.01); C07D 401/12 (2006.01); A61K 31/4439 (2006.01); C07D 401/14 (2006.01); C07D 231/12 (2006.01); A61K 31/497 (2006.01); C07D 417/12 (2006.01); C07D 405/14 (2006.01); A61K 31/4545 (2006.01); A61K 31/4709 (2006.01); A61K 31/496 (2006.01); A61K 31/4525 (2006.01); A61J 1/03 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 31/404 (2013.01); A61K 31/415 (2013.01); A61K 31/44 (2013.01); A61K 31/444 (2013.01); A61K 31/4418 (2013.01); A61K 31/4439 (2013.01); A61K 31/4525 (2013.01); A61K 31/4545 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/497 (2013.01); C07D 209/42 (2013.01); C07D 213/82 (2013.01); C07D 213/84 (2013.01); C07D 231/12 (2013.01); C07D 231/14 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 417/12 (2013.01); A61J 1/035 (2013.01);
Abstract

The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R, R, R, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

Find Patent Forward Citations

Loading…